Related Experiment Video

Updated: Apr 29, 2026

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
10:13

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment

Published on: June 21, 2022

1.7K

Alternative pharmacologic therapy for aggressive central giant cell granuloma: denosumab

Willem H Schreuder1, Annet W Coumou2, Peter A H W Kessler3

  • 1Oral and Maxillofacial Surgeon, Department of Oral and Maxillofacial Surgery, Academic Medical Center, Academic Center Dentistry Amsterdam, University of Amsterdam, Amsterdam, The Netherlands; Fellow Head and Neck Surgery, Department of Head and Neck Surgery, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands.

Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons
|May 20, 2014
PubMed

Insights

Central giant cell granuloma (CGCG) treatment can be challenging. Denosumab, an antiresorptive agent, showed success in treating an aggressive maxillary CGCG when other therapies failed, offering a potential alternative to surgery.

Area of Science:

  • Oral and Maxillofacial Surgery
  • Pharmacology
  • Oncology

Background:

  • Central giant cell granuloma (CGCG) is a rare bone tumor.
  • Osteoclastogenesis is crucial in CGCG development.
  • Effective pharmacologic therapies for CGCG are limited.

Purpose of the Study:

  • To report a case of aggressive maxillary CGCG successfully treated with denosumab.
  • To evaluate denosumab as a potential pharmacologic therapy for CGCG.

Main Methods:

  • Case report of a 25-year-old patient with maxillary CGCG.
  • Treatment with denosumab after failure of other pharmacologic agents.
  • Assessment of tumor regression and stabilization.

Main Results:

  • Successful regression and stabilization of aggressive maxillary CGCG with denosumab.
  • Denosumab demonstrated efficacy where other treatments failed.

Conclusions:

  • Denosumab may be a promising alternative to surgery for CGCG.
  • Further research is required to establish denosumab's role in CGCG treatment.

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

6.8K
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

26.8K

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
2.2K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
876
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K